Essential Partners’s Actuate Therapeutics ACTU Stock Holding History

Essential Partners’s Portfolio ACTU Stock Details ACTU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-167	Closed	-$256	–	3023
2026 Q2	$256	Buy	167 +119	+248%	+$276	﹤0.01%	2599
2026 Q1	$132	Buy	+48	New	+$199	﹤0.01%	2678

Other funds holding ACTU

Gleason Group Prospect, Kentucky $1.13B AUM 12.68% 1-Year Est. Return

GRWP

Green Ridge Wealth Planning Montville, New Jersey $249M AUM 26.89% 1-Year Est. Return

FIA

FNY Investment Advisers New York $402M AUM 85.34% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

Essential Partners's ACTU Position: Q3 2026 in Review

Essential Partners sold out of Actuate Therapeutics (ACTU) in Q3 2026, closing a stake of 167 shares — an estimated $256 sold.

Essential Partners first reported a position in ACTU in Q1 2026 and held it in 2 quarters. The position peaked at $256 in Q2 2026. 4 funds tracked by Wall St. Rank hold ACTU as of Q3 2026.

Essential Partners reported no remaining Actuate Therapeutics position as of Q3 2026 after selling out during the quarter.
Essential Partners sold 167 Actuate Therapeutics shares in Q3 2026, an estimated $256.
Essential Partners first reported a position in Actuate Therapeutics in Q1 2026 and held it in 2 quarters.
Essential Partners's Actuate Therapeutics position peaked at $256 in Q2 2026.
4 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q3 2026.

Based on Essential Partners's 13F filing for Q3 2026, filed 14 Oct 2026.